Truveta Hires Former Regeneron Executive as President and Chief Scientific Officer to Drive Next Growth Phase

New updates have been reported about Truveta.

Truveta has strengthened its senior leadership team by appointing Johnathan M. Lancaster, MD, PhD as President and Chief Scientific Officer, a move aimed at accelerating the company’s strategy to build a leading real-world evidence and intelligence platform for healthcare. Lancaster, a veteran in oncology, cancer genomics, and precision medicine, will oversee Truveta’s scientific strategy and its ecosystem partnerships with health systems, life sciences companies, and regulators, positioning the company to expand its role in regulatory-grade evidence generation, AI-driven insights, and genomic-enabled research. CEO and co-founder Terry Myerson framed the hire as a pivotal step in Truveta’s next chapter, highlighting Lancaster’s cross-sector experience in oncology, molecular genetics, and life science innovation as critical to uniting science, medicine, and technology in service of faster, better clinical decisions.

Lancaster’s appointment comes as Truveta moves to integrate de-identified genomic data at scale with extensive clinical data from its U.S. health system owners, enabling more sophisticated real-world evidence for drug development, clinical practice, and regulatory use. CTO and co-founder Jay Nanduri emphasized that Truveta’s innovation model depends on tight collaboration between technologists and clinicians, suggesting that Lancaster’s background will help convert the company’s AI and data capabilities into clinically meaningful, commercially relevant insights. Chief Medical Officer and co-founder Ryan Ahern underscored the importance of data quality and timeliness for Truveta’s customers, noting that Lancaster’s academic and oncology credentials align with the company’s push into precision healthcare and oncology-focused use cases. Lancaster, formerly Senior Vice President and Head of Global Medical Affairs at Regeneron and previously Global Chief Medical Officer at Myriad Genetics, said Truveta is now positioned to build a “definitive real-time intelligence platform for healthcare” that can inform regulatory and clinical decisions and improve outcomes globally, signaling an intensified focus on life sciences partnerships, oncology and genomics applications, and scaled commercialization of real-world evidence offerings.